James Pearson
Medical · Corning, CANPI 1598756942
Payments from drug & device makers
Across 624 payments — averaging $18.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$920
- GSK$904
- Novo Nordisk$789
- Boehringer Ingelheim$702
- Lilly USA, LLC$639
- plus $4K from 37 others
What the payments were for
- Food & beverage$11,60498%
- Education$1852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,789 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 167 | $192,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 137 | $101,349 |
| MounjaroTirzepatide | 79 | $78,020 |
| RybelsusSemaglutide | 42 | $75,130 |
| EliquisApixaban | 59 | $62,208 |
| OzempicSemaglutide | 56 | $52,429 |
| TrulicityDulaglutide | 34 | $33,641 |
| MyrbetriqMirabegron | 27 | $20,676 |
| Ondansetron Hcl | 51 | $18,879 |
| EntrestoSacubitril/Valsartan | 15 | $17,455 |
| FarxigaDapagliflozin Propanediol | 23 | $15,591 |
| JanuviaSitagliptin Phosphate | 17 | $14,633 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $12,770 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $10,231 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $10,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $702 | $192,426167 claims |
| Novo NordiskRybelsus, Ozempic | $789 | $127,55998 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $904 | $118,542170 claims |
| Lilly USA, LLCMounjaro, Trulicity, Olanzapine | $639 | $114,251199 claims |
| PfizerEliquis | $375 | $62,20859 claims |
| Astellas Pharma US IncMyrbetriq | $417 | $20,67627 claims |
| AstraZenecaFarxiga | $395 | $15,59123 claims |
| MerckJanuvia | $51 | $14,63317 claims |
| AbbVieLinzess | $3,416 | $6,96213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Corning
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- David DoriguzziLancaster$514K
- Alison GracomIrvine$467K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- Deirdre MoxleyFullerton$149K
- Tri leGardena$127K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.